23704552|t|Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models".
23704552|a|Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrated in a mouse model for Alzheimer's disease (AD) that treatment of APP/PS1DeltaE9 mice with bexarotene decreased Abeta pathology and ameliorated memory deficits. We confirm the reversal of memory deficits in APP/PS1DeltaE9 mice expressing human APOE3 or APOE4 to the levels of their nontransgenic controls and the significant decrease of interstitial fluid Abeta, but not the effects on amyloid deposition.
23704552	90	92	AD	Disease	MESH:D000544
23704552	93	98	mouse	Species	10090
23704552	208	213	mouse	Species	10090
23704552	224	243	Alzheimer's disease	Disease	MESH:D000544
23704552	245	247	AD	Disease	MESH:D000544
23704552	282	286	mice	Species	10090
23704552	292	302	bexarotene	Chemical	MESH:D000077610
23704552	313	318	Abeta	Gene	11820
23704552	345	360	memory deficits	Disease	MESH:D008569
23704552	389	404	memory deficits	Disease	MESH:D008569
23704552	423	427	mice	Species	10090
23704552	439	444	human	Species	9606
23704552	445	450	APOE3	Gene	348
23704552	454	459	APOE4	Gene	348
23704552	557	562	Abeta	Gene	11820
23704552	587	605	amyloid deposition	Disease	MESH:D058225
23704552	Negative_Correlation	MESH:D008569	348
23704552	Negative_Correlation	MESH:D000077610	MESH:D008569
23704552	Negative_Correlation	MESH:D000077610	MESH:D000544
23704552	Negative_Correlation	MESH:D000077610	11820

